GlassScriptPhysician profile
Michael Majetic
NPI 1629577119
$5,797.50
in general payments reported to CMS, 2019-2025
33 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,057 · 2022: $1,215 · 2023: $1,290 · 2024: $1,101 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,242.04 | 2021-2025 | |
| Lilly USA, LLC | $621.91 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $614.32 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $557.91 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $446.94 | 2021-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $287.12 | 2022-2025 | |
| Pfizer INC. | $189.24 | 2023-2025 | |
| Exact Sciences Corporation | $176.96 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $167.68 | 2021-2025 | Nexletol, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.22 | 2021-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $127.59 | 2021-2022 | |
| Amgen INC. | $124.21 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Sumitomo Pharma America, INC. | $107.33 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $106.04 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.19 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $94.20 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $93.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.72 | 2022-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $68.94 | 2022-2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.81 | 2025 | Caplyta |
| Dexcom, INC. | $49.88 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $43.03 | 2023-2024 | Veozah |
| Corcept Therapeutics | $38.51 | 2025 | Korlym |
| Renalytix Ai, INC. | $37.98 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Amarin Pharma, INC. | $36.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.88 | 2023-2024 | Quviviq |
| Edwards Lifesciences Corporation | $23.32 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $22.41 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $16.39 | 2021 | |
| Allergan, INC. | $15.92 | 2021 | |
| Upsher-Smith Laboratories LLC | $14.24 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Majetic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.